title: [A multicenter clinic study of slow-release-gliclazide in type 2 diabetes mellitus].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of 30 mg slow-release-gliclazide (Diamicron MR) on type 2 diabetes patients with the level of blood glucose poorly controlled formerly.
  
  
  METHODS
  154 type 2 diabetes patients with the level of blood glucose poorly controlled formerly were enrolled and treated with Diamicron MR for 16 weeks. The efficacy of slow-release-gliclazide was evaluated through HbA1c, FPG and 2 h PBG after 16 weeks of treatment period. The safety was evaluated through the adverse events including hypoglycemic episodes and the change of vital signs and clinic laboratory parameters.
  
  
  RESULTS
  After 16 weeks of treatment period, the HbA1c, FPG and 2 h PBG were decreased by 1.89%, 2.31 mmol/L and 3.94 mmol/L respectively, cutting down 21.6%, 24.5% and 27.8% relatively in comparison with pre-treatment. Glucose metabolism could be significantly improved by taking once-daily Diamicron MR.
  
  
  CONCLUSIONS
  Slow-release-gliclazide offers the significant treatment safely, which is important to optimize type 2 diabetes mellitus management.
authors.affiliation: Shanghai Diabetes Institute, Department of Endocrinology & Metabolism, Shanghai No.6 People's Hospital Affiliated to Jiaotong University, Shanghai 200233, China.
authors.forename: Wei-ping
authors.initials: WP
authors.lastname: Jia
authors.forename: Guang
authors.initials: G
authors.lastname: Ning
authors.forename: Xin
authors.initials: X
authors.lastname: Gao
authors.forename: Li
authors.initials: L
authors.lastname: Yan
authors.forename: Hua-zhang
authors.initials: HZ
authors.lastname: Yang
authors.forename: Ming
authors.initials: M
authors.lastname: Li
authors.forename: Jie
authors.initials: J
authors.lastname: Hong
authors.forename: Zhi-qiang
authors.initials: ZQ
authors.lastname: Lu
authors.forename: Hua
authors.initials: H
authors.lastname: Cheng
authors.forename: Yi-qin
authors.initials: YQ
authors.lastname: Qi
authors.forename: Zhong-wen
authors.initials: ZW
authors.lastname: Li
authors.forename: Kun-san
authors.initials: KS
authors.lastname: Xiang
mesh_terms: D000328:Adult; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D005907:Gliclazide / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D005907:Gliclazide